Print

Executive Insights

Volume XIX, Issue 1 | January 5, 2017 | By: Clay Heskett, Helen Chen, Peter Rosenorn, David Barrow Four forces driving global healthcare trends Major causes of morbidity Healthcare spend for selected countries (2015 vs. 2018) Across regions, payers are becoming more rigorous at restricting access to medicines

Developing therapeutics and medical devices for global healthcare markets remains a risky proposition. The medical innovations now coming to market are remarkable and reflect the reaction of healthcare companies towards innovation a decade ago. Globally, the biopharma and medtech sectors are being shaped by four significant forces, which will determine the success factors for the next generation of healthcare products. In this Executive Insights, L.E.K. examines each of the key forces driving change.

Volume XVIII, Issue 46 | December 2, 2016 | By: Kevin Grabenstatter, Wiley Bell Healthcare Reform Initiatives

What will the transition to a Trump administration mean for the healthcare industry’s key constituents? While experts of all stripes are asserting predictions, they are typically long on speculation and short on evidence. In a moment of political uncertainty, it is most useful to know which issues and stakeholder “tensions” to watch closely. This Executive Insights will highlight some of these questions.

Volume XVIII, Issue 43 | November 1, 2016 | By: Brian Baranick, Alex Vadas Genomics research leading to clinical genomics Genomics trends and key innovators

Remarkable advances in genomics technologies bring the promise of extraordinary changes in healthcare — and some of those changes are arriving now. What’s unfolding are nine trends that we think will shape the life sciences markets in this accelerating genomics revolution.

Volume XVIII, Issue 36 | October 12, 2016 | By: Alex Vadas, Brian Baranick Potential leakage drivers Tests and diagnostics for HER2 Dako HercepTest interpretation manual breast cancer TKI susceptibility

Companion diagnostic tests are indispensable to personalized medicine but the commercialization of these tests raises challenges for biopharma companies. This Executive Insights analyzes key issues and strategies that these companies should consider to minimize patient leakage and maximize access to drugs with CDx.

Volume XVIII, Issue 32 | October 6, 2016 | By: Marcelo do Ó Cancer incidence according to location and sex, 2014 Age and sex adjusted expected number of cases in Brazil Lymphoid Leukemia patients in Brazil, 2014 Patient identification challenges

Brazil represents one of the largest opportunities for oncology drugs where global sales exceed $100 billion. In this Executive Insights, we take an in-depth look at the opportunities for cancer care in Brazil and outline how pharmaceutical companies can improve treatment outcomes and increase revenues.

Volume XVIII, Issue 30 | August 9, 2016 | By: Peter Smith L.E.K.'s Seven Step Dynamic Performance Management Process Metrics that Reflect How the Business Really Works Economic Framework to Model Future Cash Flows Critical KPI Identification KPI Prioritization Matrix Data Capture Process and New Supporting Technologies

There are only a few KPIs which have a large influence on profitability – but defining and understanding how they interact with each other can be difficult. L.E.K. has developed a Dynamic Performance Management tool which can help businesses to address this problem and improve profitability by more than 30%.

Volume XVIII, Issue 7 | March 21, 2016 | By: Jonathan Kfoury Levels of Antimicrobial Resistance in Humans and Animals Risks Associated With Concurrent Use of Antibiotics in Animals and Humans Antimicrobial Innovation

As we’ve discussed in previous Executive Insights, antimicrobial resistance (AMR) is a growing threat to public health across the globe, creating huge implications for human and animal health. In this Executive Insights, we explore the evolving industry dynamics and implications for the animal health industry and lay out opportunities for the industry to turn this trend from a threat to a driver for growth.

Volume XVIII, Issue 2 | February 5, 2016 | By: Pierre Jacquet, David Barrow, Peter Rosenorn Biopharma Operational Scale Up Before First Product Launch Biopharma Engagement Models in the U.S. and Europe for First Product Launch Biopharma Customer-Oriented Operating Model Biopharma Tracking Tools for Enterprise Readiness

In this Executive Insights, we address the key principles that biopharma executives should bear in mind when transitioning a biopharma organization from purely research and development to an established, fully integrated drug company. Learn about L.E.K.’s proprietary approach to enterprise readiness and how it can be used successfully in operational scale up.

Volume XVII, Issue 38 | December 29, 2015 | By: Jonathan Kfoury, Alex Vadas Comparison of Various Pathogen Detection Technologies Impact of Emerging Dx Techniques on Antibiotic Treatment Paradigm

Approximately 700,000 deaths annually are caused by antimicrobial-resistant microorganisms, and the Organization for Economic Co-operation and Development (OECD) predicts that current rates of antibiotic resistance will result in cumulative costs of roughly $3 trillion by 2050. In this Executive Insights, we outline several challenges that have limited the use of diagnostic testing to drive early-line treatment decisions for serious bacterial infections, as well as our recommendations for the path forward.

Volume XVII, Issue 28 | August 19, 2015 | By: Brian Baranick, Alex Vadas Key CDx Development and Commercialization Steps and Partner Types Approved Personalized Medicine Oncology Drugs as of 20141 Examples of Drivers of CDx-Related Patient Leakage Examples of How Reference Labs Can Support CDx Commercialization

With the move toward more personalized medicine plans outside of just oncology, biopharma companies are developing more companion diagnostic (CDx) tests to give patients access to new therapies. In this Executive Insights, L.E.K. addresses CDx test barriers to commercialization and recommends partnering with large reference laboratories to avoid overtaxing IVD companies.

Pages